Oral Azithromycin Equivalent to Six Weeks Doxycycline for Meibomian Gland Dysfunction

Equivalence seen in total meibomian gland dysfunction score and Ocular Surface Disease Index score; no more adverse effects seen in azithromycin group

eye vision
Adobe Stock

FRIDAY, March 31, 2023 (HealthDay News) -- Three weeks of oral azithromycin seems to be equivalent to six weeks of doxycycline for treatment of severe meibomian gland dysfunction (MGD), according to a study published online March 23 in JAMA Ophthalmology.

Phit Upaphong, M.D., from Chiang Mai University in Thailand, and colleagues conducted a randomized trial involving patients with moderate-to-severe MGD who were randomly assigned to receive oral azithromycin (1 g once per week for three weeks) or oral doxycycline (200 mg daily for six weeks). Overall, 137 eyes from 137 patients were randomly assigned to the azithromycin and doxycycline groups (68 and 69 eyes, respectively).

The researchers found that the adjusted mean between-group difference of total MGD scores was −0.33 and 0.13 at weeks 6 and 8, respectively. At six and eight weeks, the adjusted mean between-group difference in Ocular Surface Disease Index score was −1.20 and −1.59, respectively. Patients treated with azithromycin had fewer gastrointestinal adverse effects (4.4 versus 15.9 percent).

"The reduced dosing of azithromycin supports its use as an alternative to doxycycline for at least six weeks," the authors write. "However, longer-term follow-up in each group would be needed to determine if these outcomes persist for this chronic condition."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Elana Gotkine

Elana Gotkine

Medically reviewed by Mark Arredondo, M.D.

Published on March 31, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ